Abstract
Ferroptosis is a kind of cell death which has distinctive features differentiating it from autophagy, necrosis and apoptosis. This iron-dependent form of cell death is described by an increase in lipid reactive oxygen species, shrinkage of mitochondria and decrease in mitochondrial cristae. Ferroptosis is involved in the initiation and progression of many diseases and is regarded as a hotspot of investigations on treatment of disorders. Recent studies have shown that microRNAs partake in the regulation of ferroptosis. The impact of microRNAs on this process has been verified in different cancers as well as intervertebral disc degeneration, acute myocardial infarction, vascular disease, intracerebral hemorrhage, preeclampsia, hemorrhagic stroke, atrial fibrillation, pulmonary fibrosis and atherosclerosis. miR-675, miR-93, miR-27a, miR-34a and miR-141 have been shown to affect iron metabolism, antioxidant metabolism and lipid metabolism, thus influencing all pivotal mechanisms in the ferroptosis process. In the current review, we summarize the role of microRNAs in ferroptosis and their involvement in the pathetiology of malignant and non-malignant disorders.
Introduction
As a newly recognized kind of cell type, ferroptosis is associated with accumulation of large amounts of iron accumulation and lipid peroxidation during the process of cell death (Li J. et al., 2020). This concept has been firstly proposed by Dixon et al. as an iron-dependent way of cell death described by an increase in lipid reactive oxygen species (ROS) (Dixon et al., 2012). It has several distinctive features that distinguishes this mode of cell death from autophagy, necrosis and apoptosis (Dixon et al., 2012; Xie et al., 2016). Lack of swelling of the cytoplasm and cell organelles and absence of cell membrane splitting differentiate ferroptosis from necrosis. Moreover, absence of cell shrinkage and chromatin condensation, lack of establishment of apoptotic bodies and absence of cytoskeleton breakdown differentiate ferrptosis from apoptosis. Finally, the typical closed bilayer membrane organizations which are produced during autophagy are never seen in ferroptosis (Li J. et al., 2020). From a morphological point of view, ferroptosis is characterized by shrinkage of mitochondria and decrease in mitochondrial cristae, features which are not seen in other types of cell death (Yagoda et al., 2007; Yang and Stockwell 2008; Dixon et al., 2012). Ballooning is a specific phenotype acquired by cells during ferroptosis, defined by the establishment of a clear, rounded cell chiefly consisting of empty cytosol (Battaglia et al., 2020). Notably, during the process of ferroptosis the cell membrane is not affected, the size of nucleus is not changed, and chromatin is not condensed. However, the intracellular content of glutathione (GSH) is depleted and activity of glutathione peroxidase 4 (GPX4) is decreased. Thus, the metabolism of lipid peroxides by GPX4 is impaired. Subsequently, oxidation lipids of by Fe2+ in a Fenton-like mode results in production of massive quantities of ROS, which induces ferroptosis (Yang and Stockwell 2008; Angeli et al., 2014). Ferroptosis is regulated by several genetic factors, most of them being involved in modulation of iron homeostasis and lipid peroxidation (Li J. et al., 2020).
Ferroptosis happens through two main routes, i.e., the extrinsic and the intrinsic pathways. While the former is called the transporter-dependent pathway, the latter is regulated by enzymes. This process is initiated by a redox imbalance between synthesis of oxidants and antioxidants due to the abnormalities in the expressions and activities of several redox-active enzymes that synthetize or detoxicate free radicals and products of oxidation of lipids. Therefore, ferroptosis is finely regulated at several phases. This ROS-associated kind of cell death is related with two major biochemical features, i.e., iron buildup and lipid peroxidation (Tang et al., 2021).
Ferroptosis is involved in the initiation and progression of many diseases and is regarded as a hotspot of investigations on treatment of disorders (Li J. et al., 2020). Recent studies have shown that microRNAs (miRNAs) partake in the regulation of ferroptosis. The impact of miRNAs on this process has been verified in different cancers as well as non-malignant conditions. In the current review, we summarize the role of miRNAs in ferroptosis and their involvement in the pathetiology of malignant and non-malignant disorders.
miRNAs effect on ferroptosis in cancers
miRNAs are a group of small-sized non-coding transcripts that can specifically bind with their target transcripts and induce its degradation or inhibit its translation. Through regulating several biological processes, these transcripts have fundamental roles in the process of development and cellular homeostasis (Liu et al., 2014). They can also affect expression of genes which has role in iron metabolism (Zolea et al., 2017). An experiment in melanoma cell lines has shown the role of miR-9 regulation of ferroptosis through influencing expression of GOT1. This miRNA could suppress expression of GOT1 through binding to 3′-UTR of GOT1 transcript. This binding leads to reduction of erastin- and RSL3-associated ferroptosis. On the other hand, miR-9 silencing could increase the response of neoplastic cells to erastin and RSL3. Moreover, the impact of miR-9 suppression in accumulation of lipid ROS and induction of ferroptosis can be abolished by suppression of glutaminolysis process (Zhang et al., 2018).
The Kaposi’s sarcoma herpes virus (KSHV)-encoded miRNAs have been shown to enhance expression of xCT which encodes a membrane-associated amino acid transporter. This process is mainly accomplished via inhibition of BACH-1, a modulator of transcription which recognizes antioxidant response elements within promoter regions. Enhancement of xCT expression by KSHV miRNAs has an important role in promotion of cell permissiveness for KSHV infection and protection of infected cells from reactive nitrogen species-induced cell death (Qin et al., 2010).
miR-17* is another miRNA that participate in the pathogenesis of cancers through influencing ferroptosis. This miRNA can inhibit activity of a number of enzymes participating in mitochondrial antioxidant pathways, namely manganese superoxide dismutase (MnSOD), GPX2 and thioredoxin reductase-2 (TrxR2). Forced up-regulation of miR-17* in PC-3 cells has decreased expressions of these antioxidant proteins through binding to their 3′-UTR. Cumulatively, miR-17* can inhibit prostate carcinogenesis via suppression of mitochondrial antioxidant enzymes (Xu et al., 2010a). Another experiment in prostate cancer has shown downregulation of mitochondrial antioxidant enzymes by miR-17-3p and subsequent enhancement of sensitivity of these cells to radiation (Xu et al., 2018).
Another study in multiple myeloma has shown that miR-17-5p regulates expression of the iron exporter ferroportin (FPN1), promote cell proliferation, enhance cell cycle progression, and suppress apoptosis. Expression of miR-17-5p is suppressed by the transcription factor Nrf2. Nrf2 also decreases FPN1 expression and enhanced accumulation of iron and production of ROS in the cells (Kong et al., 2019).
miR-18a is another miRNA which is involved in the regulation of ferroptosis. This miRNA has been shown to suppress expression of ALOXE3 in glioblastoma cells. Besides, ALOXE3 knock-down has enhanced secretion of 12-HETE from glioblastoma cells, decreasing migration of these cells through activation of GsPCR/PI3K/Akt axis (Yang X. et al., 2021).
miR-20a has also been shown to regulate expression of FPN through binding to its 3′-UTR. Experiments in lung cancer cells have shown that down-regulation of FPN increases cell proliferation and colony formation, most probably through enhancing iron accessibility for neoplastic cells (Babu and Muckenthaler 2016).
In liver cancer cells, miR-18a has been shown to reduce expression of GCLC- a gene that regulates biosynthesis of glutathione. miR-18a also reduces GSH levels in tumor tissues (Anderton et al., 2017). Moreover, in this type of cancer, miR-22 targets TfR1 and inhibits cell cycle progression and growth (Greene et al., 2013). Besides, miR-152 is another miRNA that regulates ferroptosis in liver cancer cells (Huang et al., 2010). Another experiment in liver cancer cells shows the role of miR-503 in reduction of intracellular levels of SOD and glutathione (Wang et al., 2014).
The role of miRNAs in the regulation of ferroptosis has also been assessed in colorectal cancer cells. In this type of cancer, miR-24-2 levels has been inversely correlated with the levels of superoxide dismutase (SOD) (He et al., 2018). Moreover, induction of ROS by GT-094 has been found to be correlated with modulation of the miR-27a:ZBTB10-Sp1/Sp3/Sp4 axis (Pathi et al., 2011). miR-145 and miR-149 are two other miRNAs that affect expression of TFR1 and DMT1 in colorectal cancer cells (Hamara et al., 2013).
Lung cancer is another type of cancer in which the role of miRNAs in the regulation of ferroptosis has been vastly investigated. For instance, miR-155 silencing has been shown to inhibit GST-π expression in A549/dox cells. miR-155 induces doxorubicin resistance via modulation of drug transportation and drug metabolism (Lv et al., 2016). miR-196a is another miRNA that has an indirect effect on ferrptosis. Suppression of this miRNA has suppressed stem cell self-renewal capacity, tumor growth and tumorigenicity through enhancement of expression of GPX3 (Liu et al., 2019). Moreover, miR-302a-3p has been found to induce ferroptosis in lung cancer cells via targeting ferroportin (Wei et al., 2021). Besides, miR-324-3p enhances cisplatin-induced ferroptosis in lung cancer cells (Deng et al., 2021).
Therefore, the effects of miRNAs on ferroptosis can be regarded as a mechanism for induction/prevention of different malignancies. Moreover, modulation of expression of ferroptosis-related miRNAs can be regarded as a potential treatment strategy for cancers. Table 1 shows the role of miRNAs in the regulation of ferroptosis in cancers.
TABLE 1
| Associated cancer type | Cell line | Study type | Upstream of miRNA | miRNA | Downstream target of miRNA | Impact on ferroptosis | Study highlights | Reference |
|---|---|---|---|---|---|---|---|---|
| Melanoma | A375, G-361 | In vitro | - | miR-9 | GOT1 | Inhibitory | miR-9 overexpression suppressed erastin- and RSL3-induced ferroptosis through Gln | Zhang et al. (2018) |
| Kaposi’s sarcoma | RAW 264.7 cells | Cell culture | - | miR-K12-11 | xCT | Indirect inhibitory effect | KSHV miRNAs can increase expression of xCT by macrophage and endothelial cells, mainly via miR-K12-11 inhibition of BACH-1, a gene that can promote ferroptosis | Qin et al. (2010) |
| Prostate cancer | PrEC, PrSC, PZ-HPV-7, HPV-18, LNCaP, DU-145, PC3 (ATCC) | Cell culture, animal models | - | miR-17 | GPX2 | Indirect effect | miR-17* can inhibit important primary mitochondrial antioxidant enzymes, namely MnSOD, GPX2 and TrxR2 | Xu et al. (2010a) |
| Prostate cancer | PC-3/22Rv1 | Cell culture, animal models | - | miR-17-3p | GPX2 | Indirect effect | Inhibition of antioxidants by miR-17-3p enhances ROS and radiotherapeutic efficiency in cancer treatment | Xu et al. (2018) |
| Multiple myeloma | ARP1 and OCI-MY5 | Cell culture, Animal models | Nrf2 | miR-17-5p | FPN | Indirect effect | Nrf2 enhances FPN1 transcription via promoter binding and suppresses miR-17-5p | Kong et al. (2019) |
| Glioma | U87 | In vitro/In vivo | - | miR-18a | ALOXE3 | Inhibitory | miR-18a targets and suppresses ALOXE3 and made glioblastoma cells resistant to p53-induced ferroptosis | Yang et al. (2021b) |
| Hepatocellular carcinoma | LT2-MYC | Cell culture, animal models | - | miR-18a | GCLC | Indirect effect | miR-18a reduces expression of GCLC- a gene that regulates biosynthesis of glutathione. miR-18a also reduces GSH levels in tumor tissues | Anderton et al. (2017) |
| Colorectal cancer | - | Clinical samples | - | miR-19a | DMT1 | Indirect effect | miR-194 levels have been associated with ferroportin concentrations | Hamara et al. (2013) |
| Lung cancer | Huh7 and NSCLC | Cell culture | - | miR-20a | FPN | Indirect effect | Downregulation of FPN by miR-20a can result in enhancement of iron pool thus providing additional iron for metabolic process | (Babu and Muckenthaler 2016) |
| Lung cancer | A549 and A549/DDP | Cell culture | - | miR-21 | - | Indirect effect | Expression levels of cystathione and GSH in A549/DDP cells were decreased after miR-21 silencing. | Dong et al. (2015) |
| Liver cancer | - | Cell culture | - | miR-22 | TFR1 | Indirect effect | miR-22 targets TfR1, and inhibits cell cycle progression and growth | Greene et al. (2013) |
| Colorectal cancer | - | Clinical samples | - | miR-24–2 | - | Indirect effect | miR-24–2 levels were inversely correlated with the levels of superoxide dismutase (SOD) | He et al. (2018) |
| Bladder cancer | EJ/T24 and RT112 | Cell culture | - | miR-27a | SLC7A11 | Indirect effect | Alterations in miR-27a levels are involved in cisplatin resistance in bladder cancer through modulating the expression of the SLC7A11 and intracellular GSH. | Drayton et al. (2014) |
| Colorectal cancer | RKO and SW480 | Cell culture | GT-094 | miR-27a | ZBTB10 | Indirect effect | Induction of ROS by GT-094 is correlated with modulation of the miR-27a:ZBTB10-Sp1/Sp3/Sp4 axis | Pathi et al. (2011) |
| Lung cancer | - | Clinical samples | - | miR-29 | IREB2 | Indirect effect | The miRNA binding site rs1062980 might change IREB2 expression via affecting miR-29a binding. This SNP can affect risk of lung cancer | Zhang et al. (2017) |
| Colorectal cancer | - | Clinical samples | - | miR-31 | TFR1 | Indirect effect | mRNA levels of TfR1are associated with miR-31 levels | Hamara et al. (2013) |
| Prostate cancer | LNCaP | Cell culture | - | miR-34b | MYC | Indirect effect | miR-34b and miR-34c can decrease c-Myc protein expression in prostate cells | Benassi et al. (2013) |
| Prostate cancer | 1E8 and 2B4 | Cell culture, animal models | - | miR-92b-5p | GST | Indirect effect | miR-92b-5p targets GSTM3, which is involved in the detoxification of electrophilic compounds by conjugation with glutathione | Ma et al. (2019) |
| Breast cancer | MDA-MB-231, T47D | In vitro/In vivo | CircRHOT1 | miR-106a-5p | STAT3 | inhibition | miR-106a-5p induced ferroptosis by targeting STAT3 in breast cancer cells | Zhang et al. (2021a) |
| Chronic lymphocytic leukemia | ATCC. MEC1 and MEC2 | Cell culture | - | miR-125b | - | Indirect effect | miR-125b affects metabolism of glucose, glutathione, lipid, and glycerolipid | Tili et al. (2012) |
| Prostate cancer | PC3, DU145 | In vitro/In vivo | LncOIP5-AS1 | miR-128-3p | SLC7A11 | inhibition | OIP5-AS1 inhibited ferroptosis under chronic exposure to Cd through targeting miR-128-3p/SLC7A11 signaling | Zhang et al. (2021b) |
| Colorectal cancer | HCT116, HT-29 | Cell culture | - | miR-129-5P | GST | Indirect effect | miR-129-5p has demonstrated dissimilar pattern of reduction in the resistant SW480 and HCT116 cell lines | Ghanbarian et al. (2018) |
| Ovarian cancer | A2780 | Cell culture | - | miR-130b | GST-π | Indirect effect | miR-130b can decrease recurrence, invasion, and metastasis of ovarian cancer | Zong et al. (2014) |
| Melanoma | A375, G-361 | In vitro/In vivo | - | miR-130b-3p | DKK1 | inhibition | miR-130b 3p suppressed erastin or RSL3 induced ferroptosis | Liao et al. (2021) |
| Breast cancer | MCF-7 | Cell culture | - | miR-133a | FTL | Indirect effect | Decrease in FTL protein levels by miR-133a enhances sensitivity of MCF-7/DOX and MCF-7/CDDP cells to doxorubicin and cisplatin | Chekhun et al. (2013) |
| Colorectal cancer | - | Clinical samples | - | miR-133a | FTL | Indirect effect | Levels of Fn have been negatively associated with IRP1 transcript levels, while positively correlated with expression of miR-133a | Hamara et al. (2013) |
| Melanoma | A375, G-361 | In vitro/In vivo | - | miR-137 | SLC1A5 | inhibition | miR-137 decreased glutamine uptake, MDA accumulation and inhibited erastin-induced ferroptosis | Luo et al. (2018) |
| Colorectal cancer | - | Clinical samples | - | miR-141 | TFR1 | Indirect effect | miR-141 can affect expression of TFR1 | Hamara et al. (2013) |
| Prostate cancer | - | Cell culture, animal models | - | miR-144 | GST | Indirect effect | miR-144 regulates expression of GSTP1 | Singh et al. (2015) |
| Colorectal cancer | - | Clinical samples | - | miR-145 | TFR1 | Indirect effect | miR-145 can affect expression of TFR1 | Hamara et al. (2013) |
| Colorectal cancer | - | Clinical samples | - | miR-149 | DMT1 | Indirect effect | miR-149 can affect expression of DMT1 | Hamara et al. (2013) |
| Hepatocellular carcinoma | HepG2, HepG2.2.15, Huh-7, LO2, and Hepa1-6 | Cell culture | - | miR-152 | DNA methyltransferase 1 | Indirect effect | Inhibition of miR-152 could enhance GSTP1 expression | Huang et al. (2010) |
| Hepatocellular carcinoma | SK-HEP1, PLC/PRF/5, Hep3B, and HepG2 | Cell culture, animal models | - | miR-152 | TFRC | Indirect effect | Up-regulation of TFRC can be involved in cancer-related abnormalities in cellular iron metabolism during liver carcinogenesis. Over-expression of TFRC can be due to down-regulation of miR-152 | Kindrat et al. (2016) |
| Prostate cancer | - | Cell culture, animal models | - | miR-153–1/2 | GSTP1 | Indirect effect | miR-153–1/2 regulate expression of GSTP1 | Singh et al. (2015) |
| Lung cancer | A549 | Cell culture | - | miR-155 | GST-π | Indirect effect | miR-155 silencing inhibited GST-π expression in A549/dox cells. miR-155 induces doxorubicin resistance via modulation of drug transportation and drug metabolism | Lv et al. (2016) |
| Colorectal cancer | - | Clinical samples | - | miR-182 | TFR1 | Indirect effect | miR-182 can affect expression of TFR1 | Hamara et al. (2013) |
| Ovarian cancer | OVCAR3, A2780, A2780/DDP, and A2780/Taxol | Cell culture | - | miR-186 | GST | Indirect effect | miR-186 has a role in induction sensitivity to paclitaxel and cisplatin through regulation of expression of ABCB1 | Sun et al. (2015) |
| Colorectal cancer | - | Clinical samples | - | miR-194 | FPN1 | Indirect effect | miR-194 can affect expression of FPN1 ferroportin 1 | Hamara et al. (2013) |
| NSCLC | A549, H460, H1975, H1650, HCC827 | Cell culture, animal models | - | miR-196a | GPX3 | Indirect effect | miR-196a suppression suppressed NSCLC stem cell self-renewal capacity, stemness, tumor growth and tumorigenicity through enhancement of expression of GPX3. | Liu et al. (2019) |
| Renal cancer | RCC4 and 786-O | Cell culture | - | miR-210 | ISCU | Indirect effect | miR-210 level is inversely correlated with ISCU levels | McCormick et al. (2013) |
| oropharyngeal squamous cell carcinomas | SCC2 and SCC38 | Cell culture | - | miR-210 | ISCU | Indirect effect | miR-210 targets ISCU. | Sáenz-de-Santa-María et al. (2017) |
| Hepatoma | HepG2, Hep3B, Hep3B rat | In vitro/In vivo | - | miR-214-3p | ATF4 | enhancement | miR-214 enhanced erastin-induced ferroptosis by targeting ATF4 | Bai et al. (2020) |
| Bladder cancer | T24 and EJ | Cell culture | - | miR-218 | GCL | Indirect effect | Over-expression of miR-218 significantly reduced the rate of glucose uptake and total level of GSH and enhanced the chemo-sensitivity of bladder cancer to cisplatin | Al-Kafaji et al. (2017) |
| NSCLC | A549, H358 | - | - | miR-302a-3p | FPN | promote | miR-302a-3p induced ferroptosis via targeting ferroportin | Wei et al. (2021) |
| Colorectal cancer | HCT116, HT-29 | Cell culture | - | miR-302c-5p | GST | Indirect effect | Over-expression of ABCB1 by miR-302c-5p defines poor response to oxaliplatin | Ghanbarian et al. (2018) |
| NSCLC | A549, DDP | In vitro | - | miR-324-3p | GPX4 | enhancement | miR-324-3p enhanced cisplatin-induced ferroptosis | (Deng et al., 2021) |
| Glioma | U87MG, U251MG, T98G, U373MG, and A172 | Cell culture | - | miR-326 | PKM2 | Indirect effect | PKM2 silencing diminished ATP and glutathione levels and activated AMPK. PKM2 is a target of the tumor-suppressive miR-326 and a potential therapeutic target in gliomas | Kefas et al. (2010) |
| Rectal cancer | - | - | CircABCB10 | miR-326 | CCL5 | inhibition | miR-326inhibits ferroptosis and apoptosis through regulation of CCL5 | Xian et al. (2020) |
| NSCLC | A549, H1299 | In vitro/In vivo | lncMT1DP | miR-365a-3p | NRF2 | enhancement | miR-365a-3p was enhanced and NRF2 was suppressed in MT1DP-overexpressing A549 and H1299 cells | Gai et al. (2020) |
| Gastric cancer | SGC-7901, BGC-823 | In vitro/In vivo | - | miR-375 | SLC7A11 | enhancement | miR-375 triggered SLC7A11-dependent ferroptosis | Ni et al. (2021a) |
| Cervical cancer | CaSki, HeLa, HcerEpic | In vitro/In vivo | circRNA_000479 | miR-375, miR-409-3P, miR-515-5p | SLC7A11 | inhibition | circEPSTI1-miR-375/409-3P/515-5p-SLC7A11 axis promoted the cervical cancer cell proliferation and its knockdown induced ferroptosis | Wu et al. (2021) |
| Ovarian cancer | - | - | - | miR-424-5p | ACSL4 | inhibition | miR-424-5p inhibits ferroptosis via targeting ACSL4 | Ma et al. (2020) |
| Glioma | U87 | Cell culture, animal models | - | miR-449a | CISD2 | Indirect effect | miR-449a targets CISD2 3′-UTR in U87 cells | Sun et al. (2017) |
| Prostate cancer | PC3 and DU145 | Cell culture, animal models | - | miR-492 | FPN | Indirect effect | miR-492 is involved in modulating MZF-1-mediated regulation on FPN and growth of prostate cancer cells | Chen et al. (2015) |
| Cervical cancer | HeLa, HeLa/DDP, and SiHa | Cell culture | - | miR-497 | - | Indirect effect | miR-497/TKT axis affects GSH and ROS levels, and enhance DDP chemoresistance in cervical cancer | Yang et al. (2016) |
| Hemangioma | HemECs | In vitro | lncMEG8 | miR-497-5p | NOTCH2 | inhibition | MEG8 silencing has suppressed proliferation and induced the ferroptosis by regulating miR-497-5p/NOTCH2 axis | Ma et al. (2021) |
| Hepatocellular carcinoma | HepG2 | Cell culture | - | miR-503 | - | Indirect effect | miR-503 increases apoptosis, blocks the cell cycle transition and reduces intracellular levels of SOD and glutathione | Wang et al. (2014) |
| Colorectal cancer and lung cancer | A549/CDDP and SPC-A-1 | Cell culture | - | miR-513a-3p | GST | Indirect effect | miR-513a-3p can sensitize human lung cancer cells to cisplatin by targeting GSTP1 | Zhang et al. (2012) |
| Oral squamous cell carcinoma | CAL27, SCC15 | In vitro/In vivo | circFNDC3B | miR-520days-5p | SLC7A11 | inhibition | circFNDC3B attenuated ferroptosis by regulating miR-520days-5p/SLC7A11 axis | Yang et al. (2021a) |
| Gastric cancer | SGC7901, MGC803, MKN45 | In vitro/In vivo | USP7, hnRNPA1 | miR-522 | ALOX15 | inhibition | miR-522 decreased ALOX15 and lipid-ROS and inhibited ferroptosis | Zhang et al. (2020a) |
| Hepatocellular carcinoma | THLE-2, HuH-7, HCCLM3 | In vitro/In vivo | CircIL4R | miR-541-3p | GPX4 | inhibition | Down-regulation of miR-541-3p relieved the ferroptosis promotion caused by circIL4R knockdown | Xu et al. (2020) |
| Thyroid cancer | Nthy-ori 3–1, FTC133, TPC-1 | In vitro/In vivo | Circ_0067934 | miR-545-3p | SLC7A11 | inhibition | miR-545-3p induced ferroptosis by targeting SLC7A11 | Wang et al. (2021a) |
| Prostate cancer | - | Cell culture, animal models | - | miR-590-3p/5p | GST | Indirect effect | miR-590-3p/5p regulate expression of GSTP1 | Singh et al. (2015) |
| Prostate cancer | DU145 and PC3 | Cell culture, animal models | - | miR-638 | FTH-1 | Indirect effect | miR-638 overexpression reduced FTH1 protein expression | Chan et al. (2018) |
| Glioblastoma | U87MG, A172 | - | - | miR-670-3p | ACSL4 | inhibition | miR-670 inhibits ferroptosis via influencing expression of ACSL4 | Bao et al. (2021) |
| Colorectal cancer | - | Clinical samples | - | miR-758 | TFR1 | Indirect effect | miR-758 can affect expression of TFR1 transferrin receptor 1 | Hamara et al. (2013) |
| Glioma | LN229, U251, NHA | In vitro/In vivo | circ-TTBK2 | miR-761 | ITGB8 | inhibition | circ-TTBK2 knockdown or miR-761 increase could promote ferroptosis | Zhang et al. (2020c) |
| Colorectal cancer | HCT116, SW620, SW480 | In vitro/In vivo | Circ_0007142 | miR-874-3p | GDPD5 | inhibition | circ_0007142 expression inhibition motivated CRC ferroptosis. Overexpression of miR-874-3p promoted ferroptosis | Wang et al. (2021b) |
| Hepatocellular carcinoma | SMMC-7721, QGY-7703 | In vitro/In vivo | circ_0013731 | miR-877-3p | SLC7A11 | inhibition | circ_0013731 mediated by E2F1 suppressed the ferroptosis via miR-877-3p/SLC7A11 axis | Fang et al. (2021) |
| Lung cancer | A549, H1975, H1650 | Cell culture | - | miR-921 | GPX3 | Indirect effect | miR-921 suppresses GPx3 expression in lung cancer cells | Choi et al. (2019) |
| Papillary thyroid cancer | KAT-5, TPC-1 | In vitro/In vivo | circKIF4A | miR-1231 | GPX4 | inhibition | GPX4 was the target of miR-1231. circKIF4A could enhance expression of GPX4. | Chen et al. (2021b) |
| Medulloblastoma | - | - | - | miR-1253 | ABCB7 | enhancement | Overexpression of miR-1253 resulted in downregulation of ABCB7 and GPX4 | Kanchan et al. (2021) |
| Hepatocellular carcinoma | LO2, HepG2, BEL-7402, MHCC-97H | In vitro/In vivo | Circ0097009 | miR-1261 | SLC7A11 | inhibition | Circ0097009 silencing enhances ferroptosis via the circ0097009/miR-1261/SLC7A11 axis | Lyu et al. (2021) |
| Colorectal cancer | HCT116, HT-29 | Cell culture | - | miR-3664-5p | GST | Indirect effect | GSTP1 levels have been correlated directly with miR-3664-5p | Ghanbarian et al. (2018) |
| NSCLC | A549 | In vitro/In vivo | - | miR-4443 | METTL3 | inhibition | Overexpression of miR-4443 inhibited cisplatin-induced ferroptosis | (Song et al., 2021c) |
| GI cancer | OE33, MKN45, STKM2 | In vitro | - | miR-4715-3p | AURKA | enhancement | miR-4715-3p induced ferroptosis by reducing GPX4 in a AURKA-dependent mechanism | Gomaa et al. (2019) |
miRNAs effect on ferroptosis in cancers.
Cumulatively, miRNAs participating in the regulation of iron metabolism, antioxidant metabolism and lipid metabolism are associated with ferroptosis process (Luo et al., 2021a). We have constructed the network between these miRNAs using the Cytoscape software. Five miRNAs, namely miR-675, miR-93, miR-27a, miR-34a and miR-141 have been found to be involved in these three metabolic pathways (Figure 1). Pre-miR-675 is produced by lncRNA H19. FTH1 silencing upregulates expressions of H19 and its cognate miR-675. Activation of H19/miR-675 participates in the FTH1 silencing-related alterations in iron metabolism (Di Sanzo et al., 2018). miR-93 regulates expression of NRF2 and has a role in breast carcinogenesis (Singh et al., 2013). miR-27a directly inhibits expression of SCD1 (Drayton et al., 2014). miR-34a directly suppresses expression of ACSL4 (Jiang et al., 2020). Finally, miR-141 inhibits Nrf2 signaling through targeting Keap1 (Wu et al., 2018).
FIGURE 1
miRNAs effects on ferroptosis in non-malignant conditions
miRNAs have important roles in the ferroptosis in non-malignant conditions. Parkinson’s disease is an example of disorders in which the role of miRNAs in the regulation of ferroptosis has been assessed. An experiment in this field has shown down-regulation of GPX4 in the animal model of this disorder in association with down-regulation of FTH1 and over-expression of miR-335. miR-335 mimic could decrease expression of FTH1, increase ferroptosis and facilitate progression of Parkinson’s disease. Mechanistically, miR-335 targets 3′-UTR of FTH1. FTH1 silencing in 6-OHDA-induced cells has increased the pro-ferroptosis impact of miR-335 and promoted pathologic events in the course of Parkinson’s disease. In fact, miR-335 enhances ferroptosis via reduction of FTH1 and subsequent enhancement of iron release, lipid peroxidation and ROS buildup, while decreasing mitochondrial membrane potential (Li X. et al., 2021). Figure 2 depicts this process.
FIGURE 2
Another experiment has shown aberrant expression of IL-6 and its receptor in cartilage samples of patients with intervertebral disc degeneration. Notably, IL-6 could down-regulate expression of miR-10a-5p, leading to derepression of IL-6R expression. IL-6 has a role in induction of ferroptosis in cartilage cells through stimulating oxidative stress and upsetting iron homeostasis. Up-regulation of miR-10a-5p could decrease IL-6R levels and attenuate IL-6-associated ferroptosis to some extent (Bin et al., 2021).
Expression of miR-15a-5p has been shown to be increased in acute myocardial infarction. miR-15a-5p silencing has decreased mortality of myocardial cells in hypoxic conditions. Notably, GPX4 has been identified as the direct target of miR-15a-5p. Up-regulation of miR-15a-5p has enhanced ferroptosis and intensified myocardial cell damage during hypoxia. Knock-down of the transcription factor Egr-1 has led to down-regulation of miR-15a-5p, and subsequent up-regulation of GPX4, which results in reduction of ferroptosis and alleviation of myocardial damage (Fan et al., 2021).
miR-17-92 is another miRNA which modulates ferroptosis. This miRNA has been shown to protect endothelial cells from erastin-associated ferroptosis. In fact, over-expression of miR-17-92 can reduce erastin-associated growth suppression and ROS production in endothelial cells. Mechanistically, miR-17-92 exerts its effects through suppression of Zinc lipoprotein A20 expression. miR-17-92 up-regulation or A20 suppression has enhanced expression of ACSL4 endothelial cells (Xiao F. J. et al., 2019).
Ferroptosis in animal model of intracerebral hemorrhage has been associated with reduced levels of miR-19b-3p and enhancement of IRP2 levels. Expression of IRP2 as a direct target of miR-19b-3p has been suppressed by miR-19b-3p mimic-transfected adipose-derived stem cells. These exosomes could also attenuate hemin-associated cell damage and ferroptosis, thus improving neurologic function in the effected animals (Yi and Tang 2021). Taken together, ferroptosis-associated miRNAs are involved in the pathogenesis of a variety of non-malignant conditions, such as intervertebral disc degeneration, acute myocardial infarction, vascular diseases, intracerebral hemorrhage and preeclampsia. Table 2 shows the role of miRNAs in regulation of ferroptosis in non-malignant conditions.
TABLE 2
| Condition | Cell line | Study type | Upstream of miRNA | miRNA | Downstream of miRNA | Effect of on ferroptosis | Study highlights | Reference |
|---|---|---|---|---|---|---|---|---|
| - | HeLa, SAS | In vitro | - | miR-7-5p | ALOX12 | inhibition | Knockdown of miR-7-5p leads to enhancement of the ferroptosis marker ALOX12 gene expression | Tomita et al. (2021) |
| Intervertebral disc degeneration | - | In vitro | IL-6 | miR-10a-5p | IL-6R | enhancement | IL-6R derepressing from miR-10a-5p enhanced IL-6 signaling | Bin et al. (2021) |
| Acute myocardial infarction | - | - | Egr-1 | miR-15a-5p | GPX4 | enhancement | miR-15a-5p enhances ferroptosis through regulation of GPX4 | Fan et al. (2021) |
| Vascular disease | HUVEC | In vitro | - | miR-17–92 | A20 | inhibition | miR-17–92 protected the HUVEC cells from erastin-induced ferroptosis maybe through miR-17–92/A20/ACSL4 axis | Xiao et al. (2019) |
| Intracerebral hemorrhage | adipose-derived stem cells(ADSCs) | In vitro/In vivo | - | Exo-miR-19b-3p | IRP2 | inhibition | Exosomal miR-19b-3p originated from ADSCs could abrogate Hemin-associated ferroptosis | (Yi and Tang 2021) |
| Acute myocardial infarction | HUCB-MSCs | In vitro/In vivo | - | Exo-miR-23a-3p | DMT1 | inhibition | HUCB-MSCs-derived miR-23a-3p-expressing exosomes suppress ferroptosis | Song et al. (2021b) |
| Preeclampsia | HTR-8/SVneo, TEV-1 | In vitro/In vivo | - | miR-30-5p | Pax3 and SLC7A11 | enhancement | Upregulation of miR-30b-5p downregulated SLC7A11, Pax3, and Pax3-downstream target, FPN1, and induces ferroptosis | (Zhang et al., 2020b) |
| Myocardial infarction | - | - | - | miR-30d | ATG5 | enhancement | miR-30days suppresses cardiomyocytes autophagy and promote ferroptosis | Tang et al. (2020) |
| - | A549, L78, NCI–H460, GLC-82, SPC-A1, PC9, BEAS-2B | In vitro/In vivo | - | miR-101-3p | TBLR1 | enhancement | Activation of the miR-101–3p/TBLR1 axis directly recovered tumor cell ferroptosis | Luo et al. (2021b) |
| Intracerebral hemorrhage | BMVECs | In vitro/In vivo | lncH19 | miR-106b-5p | ACSL4 | enhancement | H19 silencing enhances cell proliferation and suppresses BMVECs ferroptosis | Chen et al. (2021a) |
| Intracerebral hemorrhage | - | In vitro/In vivo | - | miR-124 | FPN | inhibition | miR-124/Fpn signaling mediates neuron death post-ICH through apoptosis and ferroptosis | Bao et al. (2020) |
| Myocardial I/R injury | H9C2 | In vitro/In vivo | - | miR-135b-3p | GPX4 | promote | miR-135b-3p promoted cellular ferroptosis by downregulating GPX4 expression | Sun et al. (2021b) |
| Hemorrhagic Stroke | SH-SY5Y | In vitro | - | Exo-miR-137 | COX2/PGE2 | inhibition | EXsmiR-137 suppresses oxyHb-induced ferroptosis | Li et al. (2020) |
| Atrial fibrillation | - | In vitro | - | miR-143-3p | GOT1 | inhibition | Overexpression of miR-143-3p inhibited ferroptosis | Song et al. (2021) |
| Pulmonary fibrosis | HFL1 | In vitro/In vivo | lncZFAS1 | miR-150-5p | SLC38A1 | enhancement | Overexpression of lncRNA ZFAS1 increased ferroptosis through decreasing the inhibitory effect of miR-150-5p on SLC38A1 expression | Ni et al. (2021) |
| MI | H9c2, HEK-293 T | In vitro | - | miR-190a-5p | GLS2 | inhibition | Upregulation of miR-190a-5p inhibited ferroptosis induced by erastin and RSL3 | Zhou et al. (2021) |
| Atherosclerosis | Endothelial progenitor cells | In vitro/In vivo | - | EV-miR-199a-3p | SP1 | inhibition | EPC-EVs carrying miR-199a-3p have an impact on the function of ECs and inhibited ferroptosis of ECs by targeting SP1 | (Li et al., 2021a) |
| TBI | HT-22, Neuro-2a | In vitro/In vivo | - | miR-212-5p | Ptgs2 | inhibition | miR-212-5p suppressed the ferroptotic neuronal death partly by targeting Ptgs2 | Xiao et al. (2019b) |
| Brain ischemia/reperfusion | PC12 rat | In vitro/In vivo | lncPVT1 | miR-214 | TP53, TFR1, PVT1 | enhancement | PVT1 silencing or miR-214 up-regulation could decrease p53 levels and increase SLC7A11 levels | Lu et al. (2020) |
| Heart Failure | HL-1 | In vitro | circSnx12 | miR-224-5p | FTH1 | inhibit | Low circSnx12 expression and high miR-224-5p expression induced ferroptosis | Zheng et al. (2021) |
| PD | PC12 | In vitro/In vivo | - | miR-335 | FTH1 | enhancement | miR-335 promoted ferroptosis in PD by inhibiting FTH1 expression | Moradi et al. (2021) |
| Chronic heart failure | HL-1 | In vitro/In vivo | - | miR-351 | MLK3 | inhibition | Enhancement of expression of miR-351 improved cardiac function in animal models | Wang et al. (2020) |
| I/R-induced renal injury | HK-2, TCMK-1 rat | In vitro/In vivo | - | miR-182-5p | GPX4 | enhancement | miR-182-5p and miR-378a-3p promoted ferroptosis in the renal epithelial cells by suppressing GPX4 and SLC7A11, respectively | Ding et al. (2020) |
| miR-378a-3p | SLC7A11 |
miRNAs effect on ferroptosis in non-malignant conditions.
Effects of different treatments on expression of ferroptosis-associated miRNAs
A number of drugs and treatments have been found to influence course of disorders through affecting expression of ferroptosis-associated miRNAs. For instance, experiments in animal models of intracerebral hemorrhage have shown that acupuncture can amend neuron cells death, inflammatory responses, and ferroptosis through downregulation of miR-23a-3p. The effects of acupuncture on alleviation of ferroptosis and reduction of miR-23a-3p expression have been verified by the observed enhancemnet of nuclear translocation of NFE2L2 and expression of heme oxygenase-1 and glutathione peroxidase 4 as well as reduction of iron and malondialdehyde levels and decrease in the accumulation of reactive oxygen species. Furthermore, antagomiR-23a-3p could inhibit the intracerebral hemorrhage-induced enhancemnet of Fluoro-Jade B-positive cells, production of proinflammatory cytokines, ferroptosis, and activity of NFE2L2. Mechanistically, miR-23a-3p has binding site on NFE2L2 (Kong et al., 2021). On the other hand, isorhynchophylline has been shown to ameliorate ferroptosis-associated nerve injury in the context of intracerebral hemorrhage through modulation of miR-122-5p (Zhao et al., 2021). Experiments in mouse hippocampal HT-22 cells exposed to ferric ammonium citrate alone or together with Isorhynchophylline have shown that Isorhynchophylline reduces the ferric ammonium citrate-associated cell injury. Isorhynchophylline also reduces the ferric ammonium citrate-induced reduction of miR-122-5p expression and ameliorates ferroptosis. Besides, miR-122-5p inhibitor could diminish the protective effect of Isorhynchophylline against ammonium citrate-associated ferroptosis in these cells. Mechanistically, miR-122-5p targets TP53, and restoration of TP53 attenuates the effect of miR-122-5p on ferroptotic markers and expression of SLC7A11. Taken together, miR-122-5p/TP53/SLC7A11 axis has been suggested as a potential mechanism in the etiology of intracranial hemorrhage (Zhao et al., 2021).
Moreover, metformin can induce ferroptosis of breast cancer cells through influencing expression of the GPX4 targeting miRNA miR-324-3p. Up-regulation of miR-324-3p has suppressed viability of breast cancer cells. In fact, metformin can be regarded as a potential anti-cancer agent via activation of ferroptosis (Hou et al., 2021). Similarly, lidocaine and levobupivacaine enhance ferroptosis of cancer cells through targeting miR-382-5p (Sun D. et al., 2021) and miR-489-3p (Mao et al., 2021), respectively.
Table 3 shows the effects of different treatments on expression of ferroptosis-associated miRNAs.
TABLE 3
| Disease | Cell line | Study type | Drug/Treatment | Regulation of miRNA by treatment | miRNA | Target | Effect of drug on ferroptosis | Study highlights | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Intracerebral hemorrhage | - | In vivo | Acupuncture | ↓ | miR-23a-3p | NFE2L2 | inhibition | Baihui-penetrating-Qubin acupuncture treatment inhibited ferroptosis after ICH via down-regulating miR-23a-3p | Kong et al. (2021) |
| Intracerebral hemorrhage | HT-22 | In vitro/In vivo | Isorhynchophylline | ↑ | miR-122-5p | TP53 | inhibition | miR-122-5p Suppresses FAC-Induced Ferroptosis by Targeting TP53 | Zhao et al. (2021) |
| Breast cancer | MDA-MB-231, MCF-7 | In vitro/In vivo | Metformin | ↑ | miR-324-3p | GPX4 | enhancement | miR-324-3p induced ferroptosis via directly targeting GPX4 | Hou et al. (2021) |
| Ovarian and Breast cancer | SKOV-3, T47D | In vitro/In vivo | Lidocaine | ↑ | miR-382-5p | SLC7A11 | enhancement | Lidocaine Inhibited SLC7A11 Expression by Upregulating miR-382-5p | Sun et al. (2021a) |
| Gastric cancer | GES-1, HGC27, SGC7901 | In vitro/In vivo | Levobupivacaine | ↑ | miR-489-3p | SLC7A11 | enhancement | Levobupivacaine induces ferroptosis of gastric cancer cells through miR-489-3p/SLC7A11 axis | Mao et al. (2021) |
Effects of drugs on ferroptosis-associated miRNAs.
Discussion
Several miRNAs have been found to affect ferroptosis through binding with 3′-UTR of genes participating in this process. GOT1, GPX2, GPX3, GPX4, FPN, GSH, GST, FTL, TFR1 and NRF2 are examples of ferroptosis-associated molecules which are regulated by miRNAs. Moreover, a number of miRNAs can affect ferroptosis through indirect routes. For instance, miR-152 can reduce expression of DNA methyltransferase one leading to global DNA hypomethylation and enhancement of expression of GSTP1 (Huang et al., 2010).
Since ferroptosis can eradicate cancer cells in an independent way from apoptosis (Zhang X. et al., 2020), identification of the role of miRNAs in this process can propose new ways for combatting cancer progression. It is worth mentioning that some of above-mentioned miRNAs that regulate ferroptosis, have additional roles in the regulation of other types of cell death. Thus, these miRNAs can induce cancer cell death from different routes.
Bioinformatics tools have facilitated identification of miRNAs with highest involvement in the ferroptosis, thus proposing the most appropriate targets for management of ferroptosis-associated disorders.
A number of long non-coding RNAs and circRNAs have been found to affect expression of ferroptosis-related miRNAs. CircRHOT1, circABCB10, circRNA_000479, circFNDC3B, circIL4R, circ_0067934, circ-TTBK2, circ_0007142, circ_0013731, circKIF4A, circ0097009, lncOIP5-AS1, lncMT1DP and lncMEG8 have been recognized as competing endogenous RNAs for miRNAs that partake in the ferroptosis. Therefore, ferroptosis can be regulated by several members of non-coding RNAs.
Notably, acupuncture and a number of drugs such as physcion 8-O-β-glucopyranoside, isorhynchophylline, metformin, lidocaine and levobupivacaine have been shown to affect ferroptosis through modulation of miRNAs. Thus, identification of the role of miRNAs in the regulation of ferroptosis can facilitate design of novel therapeutic agents for treatment of diverse neoplastic or neurodegenerative disorders.
Based on the vast impact of ferroptosis on development of disorders, therapies targeting this process can be proposed as treatment modalities for several disorders including neoplastic and neurodegenerative disorders. Manipulation of expression of ferroptosis-associated miRNAs through different methods is regarded as a potential strategy to affect ferroptosis and intervene with the pathoetiology of mentioned disorders. Since ferroptosis might have opposite effects on the physiology of organs, context-based strategies are needed in this regard. Other issues that should be addressed before incorporation of miRNA-based therapies in the clinical settings are identification of safe and efficient methods for delivery of these kinds of therapies into the specific cells and monitoring the cellular response to these modalities.
Ferroptosis-related miRNAs can alter response of cancer cells to chemotherapeutic modalities. Therefore, manipulation of expression of these miRNAs not only affects the progression and evolution of cancer, but also influences the response to a variety of treatment options. In spite of extensive research on effectiveness of these modalities in cancer cell lines and animal models, there is no clinical trial for appraisal of these methods in the clinical settings. However, it is expected that combination of miRNA-based therapies with conventional or targeted anti-cancer therapies enhances the effectiveness of these therapies. Since cancer cells are heterogeneous in terms of miRNAs signature, it is necessary to have a miRNA profile for each patient before implementation of these novel methods in the clinical settings.
Statements
Author contributions
SG-F wrote the manuscript and revised it. SK, RM-L, and BH collected the data and designed the figures and tables. All authors read and approved the submitted version.
Funding
This study was financially supported by Grant from Medical School of Shahid Beheshti University of Medical Sciences.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
reactive oxygen species; (ROS), glutathione peroxidase 4; (GPX4), Kaposi’s sarcoma herpes virus; (KSHV), manganese superoxide dismutase; (MnSOD), thioredoxin reductase-2; (TrxR2), ferroportin; (FPN1), glutamic-oxaloacetic transaminase 1; (GOT1), Glutathione; (GSH), glutathione S-transferase; (GST), Fms-like tyrosine kinase 3; (FTL3), transferrin receptor 1; (TFR1), Nuclear factor erythroid 2-related factor 2; (NRF2).
References
1
Al-KafajiG.Al-MahroosG.Abdulla Al-MuhtareshH.SabryM. A.Abdul RazzakR.SalemA. H. (2017). Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients. Biomarkers22 (3-4), 268–278. 10.1080/1354750X.2016.1204004
2
AndertonB.CamardaR.BalakrishnanS.BalakrishnanA.KohnzR. A.LimL.et al (2017). MYC‐driven inhibition of the glutamate‐cysteine ligase promotes glutathione depletion in liver cancer. EMBO Rep.18 (4), 569–585. 10.15252/embr.201643068
3
AngeliJ. P. F.SchneiderM.PronethB.TyurinaY. Y.TyurinV. A.HammondV. J.et al (2014). Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol.16 (12), 1180–1191. 10.1038/ncb3064
4
BabuK. R.MuckenthalerM. U. (2016). miR-20a regulates expression of the iron exporter ferroportin in lung cancer. J. Mol. Med.94 (3), 347–359. 10.1007/s00109-015-1362-3
5
BaiT.LiangR.ZhuR.WangW.ZhouL.SunY. (2020). MicroRNA-214-3p enhances erastin-induced ferroptosis by targeting ATF4 in hepatoma cells. J. Cell Physiol.235 (7-8), 5637–5648. 10.1002/jcp.29496
6
BaoC.ZhangJ.XianS. Y.ChenF. (2021). MicroRNA-670-3p suppresses ferroptosis of human glioblastoma cells through targeting ACSL4. Free Radic. Res.55, 853–864. 10.1080/10715762.2021.1962009
7
BaoW. D.ZhouX. T.ZhouL. T.WangF.YinX.LuY.et al (2020). Targeting miR-124/Ferroportin signaling ameliorated neuronal cell death through inhibiting apoptosis and ferroptosis in aged intracerebral hemorrhage murine model. Aging Cell19 (11), e13235. 10.1111/acel.13235
8
BattagliaA. M.ChirilloR.AversaI.SaccoA.CostanzoF.BiamonteF. (2020). Ferroptosis and cancer: Mitochondria meet the “iron maiden” cell death. Cells9 (6), 1505. 10.3390/cells9061505
9
BenassiB.MaraniM.LodaM.BlandinoG. (2013). USP2a alters chemotherapeutic response by modulating redox. Cell death Dis.4 (9), e812. 10.1038/cddis.2013.289
10
BinS.XinL.LinZ.JinhuaZ.RuiG.XiangZ. (2021). Targeting miR-10a-5p/IL-6R axis for reducing IL-6-induced cartilage cell ferroptosis. Exp. Mol. Pathol.118, 104570. 10.1016/j.yexmp.2020.104570
11
ChanJ. J.KwokZ. H.ChewX. H.ZhangB.LiuC.SoongT. W.et al (2018). A FTH1 gene: Pseudogene: microRNA network regulates tumorigenesis in prostate cancer. Nucleic acids Res.46 (4), 1998–2011. 10.1093/nar/gkx1248
12
ChekhunV. F.LukyanovaN. Y.BurlakaА. P.BezdenezhnykhN. A.ShpylevaS. I.TryndyakV. P.et al (2013). Iron metabolism disturbances in the MCF-7 human breast cancer cells with acquired resistance to doxorubicin and cisplatin. Int. J. Oncol.43 (5), 1481–1486. 10.3892/ijo.2013.2063
13
ChenB.WangH.LvC.MaoC.CuiY. (2021a). Long non-coding RNA H19 protects against intracerebral hemorrhage injuries via regulating microRNA-106b-5p/acyl-CoA synthetase long chain family member 4 axis. Bioengineered12 (1), 4004–4015. 10.1080/21655979.2021.1951070
14
ChenW.FuJ.ChenY.LiY.NingL.HuangD.et al (2021b). Circular RNA circKIF4A facilitates the malignant progression and suppresses ferroptosis by sponging miR-1231 and upregulating GPX4 in papillary thyroid cancer. Aging (Albany NY)13 (12), 16500–16512. 10.18632/aging.203172
15
ChenY.ZhangZ.YangK.DuJ.XuY.LiuS. (2015). Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress. Oncogene34 (29), 3839–3847. 10.1038/onc.2014.310
16
ChoiJ.-Y.AnB. C.JungI. J.KimJ. H.LeeS.-w. (2019). MiR-921 directly downregulates GPx3 in A549 lung cancer cells. Gene700, 163–167. 10.1016/j.gene.2019.02.086
17
DengS. H.WuD. M.LiL.LiuT.ZhangT.LiJ.et al (2021). miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549. Biochem. Biophys. Res. Commun.549, 54–60. 10.1016/j.bbrc.2021.02.077
18
Di SanzoM.ChirilloR.AversaI.BiamonteF.SantamariaG.GiovannoneE.et al (2018). shRNA targeting of ferritin heavy chain activates H19/miR-675 axis in K562 cells. Gene657, 92–99. 10.1016/j.gene.2018.03.027
19
DingC.DingX.ZhengJ.WangB.LiY.XiangH.et al (2020). miR-182-5p and miR-378a-3p regulate ferroptosis in I/R-induced renal injury. Cell Death Dis.11 (10), 929. 10.1038/s41419-020-03135-z
20
DixonS. J.LembergK. M.LamprechtM. R.SkoutaR.ZaitsevE. M.GleasonC. E.et al (2012). Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell149 (5), 1060–1072. 10.1016/j.cell.2012.03.042
21
DongZ.RenL.LinL.LiJ.HuangY.LiJ. (2015). Effect of microRNA-21 on multidrug resistance reversal in A549/DDP human lung cancer cells. Mol. Med. Rep.11 (1), 682–690. 10.3892/mmr.2014.2662
22
DraytonR. M.DudziecE.PeterS.BertzS.HartmannA.BryantH. E.et al (2014). Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin. cancer Res.20 (7), 1990–2000. 10.1158/1078-0432.CCR-13-2805
23
FanK.HuangW.QiH.SongC.HeC.LiuY.et al (2021). The Egr-1/miR-15a-5p/GPX4 axis regulates ferroptosis in acute myocardial infarction. Eur. J. Pharmacol.909, 174403. 10.1016/j.ejphar.2021.174403
24
FangS.ChenW.DingJ.ZhangD.ZhengL.SongJ.et al (2021). "Oxidative Medicine and Cellular Longevity Hsa_circ_0013731 mediated by E2F1 inhibits ferroptosis in hepatocellular carcinoma cells by sponging miR-877-3p and targeting SLC7A11."
25
GaiC.LiuC.WuX.YuM.ZhengJ.ZhangW.et al (2020). MT1DP loaded by folate-modified liposomes sensitizes erastin-induced ferroptosis via regulating miR-365a-3p/NRF2 axis in non-small cell lung cancer cells. Cell Death Dis.11 (9), 751. 10.1038/s41419-020-02939-3
26
GhanbarianM.AfgarA.YadegarazariR.NajafiR.Teimoori-ToolabiL. (2018). Through oxaliplatin resistance induction in colorectal cancer cells, increasing ABCB1 level accompanies decreasing level of miR-302c-5p, miR-3664-5p and miR-129-5p. Biomed. Pharmacother.108, 1070–1080. 10.1016/j.biopha.2018.09.112
27
GomaaA.PengD.ChenZ.SouttoM.AbouelezzK.CorvalanA.et al (2019). Epigenetic regulation of AURKA by miR-4715-3p in upper gastrointestinal cancers. Sci. Rep.9 (1), 16970. 10.1038/s41598-019-53174-6
28
GreeneC. M.VarleyR. B.LawlessM. W. (2013). MicroRNAs and liver cancer associated with iron overload: Therapeutic targets unravelled. World J. gastroenterology WJG19 (32), 5212–5226. 10.3748/wjg.v19.i32.5212
29
HamaraK.Bielecka-KowalskaA.Przybylowska-SygutK.SygutA.DzikiA.SzemrajJ. (2013). Alterations in expression profile of iron-related genes in colorectal cancer. Mol. Biol. Rep.40 (10), 5573–5585. 10.1007/s11033-013-2659-3
30
HeH. W.WangN. N.YiX. M.TangC. P.WangD. (2018). Low-level serum miR-24-2 is associated with the progression of colorectal cancer. Cancer Biomarkers21 (2), 261–267. 10.3233/CBM-170321
31
HouY.CaiS.YuS.LinH. (2021). Metformin induces ferroptosis by targeting miR-324-3p/GPX4 axis in breast cancer. Acta Biochim. Biophys. Sin. (Shanghai)53 (3), 333–341. 10.1093/abbs/gmaa180
32
HuangJ.WangY.GuoY.SunS. (2010). Down‐regulated microRNA‐152 induces aberrant DNA methylation in Hepatitis B virus–related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology52 (1), 60–70. 10.1002/hep.23660
33
JiangX.GuoS.ZhangY.ZhaoY.LiX.JiaY.et al (2020). LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p. Cell. Signal.65, 109422. 10.1016/j.cellsig.2019.109422
34
KanchanR. K.PerumalN.AtriP.VenkataR. C.ThapaI.NasserM. W.et al (2021). "MiR-1253 potentiates cisplatin response in pediatric medulloblastoma by regulating ferroptosis."
35
KefasB.ComeauL.ErdleN.MontgomeryE.AmosS.PurowB. (2010). Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-oncology12 (11), 1102–1112. 10.1093/neuonc/noq080
36
KindratI.TryndyakV.de ContiA.ShpylevaS.MudaligeT. K.KobetsT.et al (2016). MicroRNA-152-mediated dysregulation of hepatic transferrin receptor 1 in liver carcinogenesis. Oncotarget7 (2), 1276–1287. 10.18632/oncotarget.6004
37
KongY.HuL.LuK.WangY.XieY.GaoL.et al (2019). Ferroportin downregulation promotes cell proliferation by modulating the Nrf2–miR-17-5p axis in multiple myeloma. Cell death Dis.10 (9), 624. 10.1038/s41419-019-1854-0
38
KongY.LiS.ZhangM.XuW.ChenQ.ZhengL.et al (2021). Acupuncture ameliorates neuronal cell death, inflammation, and ferroptosis and downregulated miR-23a-3p after intracerebral hemorrhage in rats. J. Mol. Neurosci.71 (9), 1863–1875. 10.1007/s12031-020-01770-x
39
LiJ.CaoF.YinH.-l.HuangZ.-j.LinZ.-t.MaoN.et al (2020a). Ferroptosis: Past, present and future. Cell death Dis.11 (2), 88–13. 10.1038/s41419-020-2298-2
40
LiL.WangH.ZhangJ.ChenX.ZhangZ.LiQ. (2021a). Effect of endothelial progenitor cell-derived extracellular vesicles on endothelial cell ferroptosis and atherosclerotic vascular endothelial injury. Cell Death Discov.7 (1), 235. 10.1038/s41420-021-00610-0
41
LiX.SiW.LiZ.TianY.LiuX.YeS.et al (2021b). miR-335 promotes ferroptosis by targeting ferritin heavy chain 1 in in vivo and in vitro models of Parkinson's disease. Int. J. Mol. Med.47 (4), 61–12. 10.3892/ijmm.2021.4894
42
LiY.WangJ.ChenS.WuP.XuS.WangC.et al (2020b). miR-137 boosts the neuroprotective effect of endothelial progenitor cell-derived exosomes in oxyhemoglobin-treated SH-SY5Y cells partially via COX2/PGE2 pathway. Stem Cell Res. Ther.11 (1), 330. 10.1186/s13287-020-01836-y
43
LiaoY.JiaX.RenY.DejiZ.GesangY.NingN.et al (2021). Suppressive role of microRNA-130b-3p in ferroptosis in melanoma cells correlates with DKK1 inhibition and Nrf2-HO-1 pathway activation. Hum. Cell34 (5), 1532–1544. 10.1007/s13577-021-00557-5
44
LiuB.LiJ.CairnsM. J. (2014). Identifying miRNAs, targets and functions. Briefings Bioinforma.15 (1), 1–19. 10.1093/bib/bbs075
45
LiuQ.BaiW.HuangF.TangJ.LinX. (2019). Downregulation of microRNA-196a inhibits stem cell self-renewal ability and stemness in non-small-cell lung cancer through upregulating GPX3 expression. Int. J. Biochem. Cell Biol.115, 105571. 10.1016/j.biocel.2019.105571
46
LuJ.XuF.LuH. (2020). LncRNA PVT1 regulates ferroptosis through miR-214-mediated TFR1 and p53. Life Sci.260, 118305. 10.1016/j.lfs.2020.118305
47
LuoM.WuL.ZhangK.WangH.ZhangT.GutierrezL.et al (2018). miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma. Cell Death Differ.25 (8), 1457–1472. 10.1038/s41418-017-0053-8
48
LuoY.HuangQ.HeB.LiuY.HuangS.XiaoJ. (2021a). Regulation of ferroptosis by non‑coding RNAs in the development and treatment of cancer (Review). Oncol. Rep.45 (1), 29–48. 10.3892/or.2020.7836
49
LuoY.NiuG.YiH.LiQ.WuZ.WangJ.et al (2021b). Nanomedicine promotes ferroptosis to inhibit tumour proliferation in vivo. Redox Biol.42, 101908. 10.1016/j.redox.2021.101908
50
LvL.AnX.LiH.MaL. (2016). Effect of miR-155 knockdown on the reversal of doxorubicin resistance in human lung cancer A549/dox cells. Oncol. Lett.11 (2), 1161–1166. 10.3892/ol.2015.3995
51
LyuN.ZengY.KongY.ChenQ.DengH.OuS.et al (2021). Ferroptosis is involved in the progression of hepatocellular carcinoma through the circ0097009/miR-1261/SLC7A11 axis. Ann. Transl. Med.9 (8), 675. 10.21037/atm-21-997
52
MaH.WangL. Y.YangR. H.ZhouY.ZhouP.KongL. (2019). Identification of reciprocal microRNA‐mRNA pairs associated with metastatic potential disparities in human prostate cancer cells and signaling pathway analysis. J. Cell. Biochem.120 (10), 17779–17790. 10.1002/jcb.29045
53
MaL. L.LiangL.ZhouD.WangS. W. (2020). Neoplasma.Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4
54
MaQ.DaiX.LuW.QuX.LiuN.ZhuC. (2021). Silencing long non-coding RNA MEG8 inhibits the proliferation and induces the ferroptosis of hemangioma endothelial cells by regulating miR-497-5p/NOTCH2 axis. Biochem. Biophys. Res. Commun.556, 72–78. 10.1016/j.bbrc.2021.03.132
55
MaoS. H.ZhuC. H.NieY.YuJ.WangL. (2021). Levobupivacaine induces ferroptosis by miR-489-3p/slc7a11 signaling in gastric cancer. Front. Pharmacol.12, 681338. 10.3389/fphar.2021.681338
56
McCormickR. I.BlickC.RagoussisJ.SchoedelJ.MoleD. R.YoungA. C.et al (2013). miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br. J. cancer108 (5), 1133–1142. 10.1038/bjc.2013.56
57
MoradiM.GoodarziN.FaramarziA.CheraghiH.HashemianA. H.JaliliC. (2021). Melatonin protects rats testes against bleomycin, etoposide, and cisplatin-induced toxicity via mitigating nitro-oxidative stress and apoptosis. Biomed. Pharmacother.138, 111481. 10.1016/j.biopha.2021.111481
58
NiH.QinH.SunC.LiuY.RuanG.GuoQ.et al (2021a). MiR-375 reduces the stemness of gastric cancer cells through triggering ferroptosis. Stem Cell Res. Ther.12 (1), 325. 10.1186/s13287-021-02394-7
59
NiT.ChenX.HuangX.PanS.LuZ. (2021b). "Inhibition of the Long non-coding RNA ZFAS1 attenuates pathogenic ferroptosis by sponging miR-150-5p to activate CCND2 against diabetic cardiomyopathy."
60
PathiS. S.JutooruI.ChadalapakaG.SreevalsanS.AnandS.ThatcherG. R. J.et al (2011). GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway. Mol. Cancer Res.9 (2), 195–202. 10.1158/1541-7786.MCR-10-0363
61
QinZ.FreitasE.SullivanR.MohanS.BacelieriR.BranchD.et al (2010). Upregulation of xCT by KSHV-encoded microRNAs facilitates KSHV dissemination and persistence in an environment of oxidative stress. PLoS Pathog.6 (1), e1000742. 10.1371/journal.ppat.1000742
62
Sáenz-de-Santa-MaríaI.Bernardo-CastiñeiraC.SecadesP.Bernaldo-de-QuirósS.RodrigoJ. P.AstudilloA.et al (2017). Clinically relevant HIF-1α-dependent metabolic reprogramming in oropharyngeal squamous cell carcinomas includes coordinated activation of CAIX and the miR-210/ISCU signaling axis, but not MCT1 and MCT4 upregulation. Oncotarget8 (8), 13730–13746. 10.18632/oncotarget.14629
63
SinghB.RongheA. M.ChatterjeeA.BhatN. K.BhatH. K. (2013). MicroRNA-93 regulates NRF2 expression and is associated with breast carcinogenesis. Carcinogenesis34 (5), 1165–1172. 10.1093/carcin/bgt026
64
SinghS.ShuklaG. C.GuptaS. (2015). MicroRNA regulating glutathione S-transferase P1 in prostate cancer. Curr. Pharmacol. Rep.1 (2), 79–88. 10.1007/s40495-014-0009-3
65
SongY.CaiW.WangJ. (2021a). Upregulation of miR-143-3p attenuates oxidative stress-mediated cell ferroptosis in cardiomyocytes with atrial fibrillation by degrading glutamic-oxaloacetic transaminase 1. Biocell45 (3), 733–744. 10.32604/biocell.2021.013236
66
SongY.WangB.ZhuX.HuJ.SunJ.XuanJ.et al (2021b). Human umbilical cord blood-derived MSCs exosome attenuate myocardial injury by inhibiting ferroptosis in acute myocardial infarction mice. Cell Biol. Toxicol.37 (1), 51–64. 10.1007/s10565-020-09530-8
67
SongZ.JiaG.MaP.CangS. (2021c). Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis. Life Sci.276, 119399. 10.1016/j.lfs.2021.119399
68
SunA. G.MengF. G.WangM. G. (2017). CISD2 promotes the proliferation of glioma cells via suppressing beclin-1-mediated autophagy and is targeted by microRNA-449a. Mol. Med. Rep.16 (6), 7939–7948. 10.3892/mmr.2017.7642
69
SunD.LiY. C.ZhangX. Y. (2021a). Lidocaine promoted ferroptosis by targeting miR-382-5p/SLC7A11 Axis in ovarian and breast cancer. Front. Pharmacol.12, 681223. 10.3389/fphar.2021.681223
70
SunK.-X.JiaoJ.-W.ChenS.LiuB.-L.ZhaoY. (2015). MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. J. ovarian Res.8 (1), 80–87. 10.1186/s13048-015-0207-6
71
SunW.ShiR.GuoJ.WangH.ShenL.ShiH.et al (2021b). miR-135b-3p promotes cardiomyocyte ferroptosis by targeting GPX4 and aggravates myocardial ischemia/reperfusion injury. Front. Cardiovasc Med.8, 663832. 10.3389/fcvm.2021.663832
72
TangD.ChenX.KangR.KroemerG. (2021). Ferroptosis: Molecular mechanisms and health implications. Cell Res.31 (2), 107–125. 10.1038/s41422-020-00441-1
73
TangS.WangY.MaT.LuS.HuangK.LiQ.et al (2020). MiR-30d inhibits cardiomyocytes autophagy promoting ferroptosis after myocardial infarction. Panminerva Med.10.23736/S0031-0808.20.03979-8
74
TiliE.MichailleJ.-J.LuoZ.VoliniaS.RassentiL. Z.KippsT. J.et al (2012). The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state. Blood, J. Am. Soc. Hematol.120 (13), 2631–2638. 10.1182/blood-2012-03-415737
75
TomitaK.NagasawaT.KuwaharaY.ToriiS.IgarashiK.RoudkenarM. H.et al (2021). MiR-7-5p is involved in ferroptosis signaling and radioresistance thru the generation of ROS in radioresistant HeLa and SAS cell lines. Int. J. Mol. Sci.22 (15), 8300. 10.3390/ijms22158300
76
WangD.ZhangN.YeY.QianJ.ZhuY. U.WangC. (2014). Role and mechanisms of microRNA-503 in drug resistance reversal in HepG2/ADM human hepatocellular carcinoma cells. Mol. Med. Rep.10 (6), 3268–3274. 10.3892/mmr.2014.2591
77
WangH. H.MaJ. N.ZhanX. R. (2021a). Circular RNA Circ_0067934 attenuates ferroptosis of thyroid cancer cells by miR-545-3p/slc7a11 signaling. Front. Endocrinol. (Lausanne)12, 670031. 10.3389/fendo.2021.670031
78
WangJ.DengB.LiuQ.HuangY.ChenW.LiJ.et al (2020). Pyroptosis and ferroptosis induced by mixed lineage kinase 3 (MLK3) signaling in cardiomyocytes are essential for myocardial fibrosis in response to pressure overload. Cell Death Dis.11 (7), 574. 10.1038/s41419-020-02777-3
79
WangY.ChenH.WeiX. (2021b). Circ_0007142 downregulates miR-874-3p-mediated GDPD5 on colorectal cancer cells. Eur. J. Clin. Invest.51 (7), e13541. 10.1111/eci.13541
80
WeiD.KeY. Q.DuanP.ZhouL.WangC. Y.CaoP. (2021). MicroRNA-302a-3p induces ferroptosis of non-small cell lung cancer cells via targeting ferroportin. Free Radic. Res.55, 821–830. 10.1080/10715762.2021.1947503
81
WuL.PanC.WeiX.ShiY.ZhengJ.LinX.et al (2018). lncRNA KRAL reverses 5-fluorouracil resistance in hepatocellular carcinoma cells by acting as a ceRNA against miR-141. Cell Commun. Signal.16 (1), 47–15. 10.1186/s12964-018-0260-z
82
WuP.LiC.YeD. M.YuK.LiY.TangH.et al (2021). Circular RNA circEPSTI1 accelerates cervical cancer progression via miR-375/409-3P/515-5p-SLC7A11 axis. Aging (Albany NY)13 (3), 4663–4673. 10.18632/aging.202518
83
XianZ. Y.HuB.WangT.CaiJ. L.ZengJ. Y.ZouQ.et al (2020). CircABCB10 silencing inhibits the cell ferroptosis and apoptosis by regulating the miR-326/CCL5 axis in rectal cancer. Neoplasma67 (5), 1063–1073. 10.4149/neo_2020_191024N1084
84
XiaoF. J.ZhangD.WuY.JiaQ. H.ZhangL.LiY. X.et al (2019a). miRNA-17-92 protects endothelial cells from erastin-induced ferroptosis through targeting the A20-ACSL4 axis. Biochem. Biophys. Res. Commun.515 (3), 448–454. 10.1016/j.bbrc.2019.05.147
85
XiaoX.JiangY.LiangW.WangY.CaoS.YanH.et al (2019b). miR-212-5p attenuates ferroptotic neuronal death after traumatic brain injury by targeting Ptgs2. Mol. Brain12 (1), 78. 10.1186/s13041-019-0501-0
86
XieY.HouW.SongX.YuY.HuangJ.SunX.et al (2016). Ferroptosis: Process and function. Cell Death Differ.23 (3), 369–379. 10.1038/cdd.2015.158
87
XuQ.ZhouL.YangG.MengF.WanY.WangL.et al (2020). CircIL4R facilitates the tumorigenesis and inhibits ferroptosis in hepatocellular carcinoma by regulating the miR-541-3p/GPX4 axis. Cell Biol. Int.44 (11), 2344–2356. 10.1002/cbin.11444
88
XuY.FangF.ZhangJ.JossonS.ClairW. H. St.ClairD. K. St. (2010). miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. PloS one5 (12), e14356. 10.1371/journal.pone.0014356
89
XuZ.ZhangY.DingJ.HuW.TanC.WangM.et al (2018). miR-17-3p downregulates mitochondrial antioxidant enzymes and enhances the radiosensitivity of prostate cancer cells. Mol. Therapy-Nucleic Acids13, 64–77. 10.1016/j.omtn.2018.08.009
90
YagodaN.von RechenbergM.ZaganjorE.BauerA. J.YangW. S.FridmanD. J.et al (2007). RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature447 (7146), 864–868. 10.1038/nature05859
91
YangH.WuX.-L.WuK.-H.ZhangR.JuL.-L.JiY.et al (2016). MicroRNA-497 regulates cisplatin chemosensitivity of cervical cancer by targeting transketolase. Am. J. cancer Res.6 (11), 2690–2699.
92
YangJ.CaoX. H.LuanK. F.HuangY. D. (2021a). Circular RNA FNDC3B protects oral squamous cell carcinoma cells from ferroptosis and contributes to the malignant progression by regulating miR-520d-5p/slc7a11 Axis. Front. Oncol.11, 672724. 10.3389/fonc.2021.672724
93
YangW. S.StockwellB. R. (2008). Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem. Biol.15 (3), 234–245. 10.1016/j.chembiol.2008.02.010
94
YangX.LiuJ.WangC.ChengK. K.XuH.LiQ.et al (2021b). miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities. Oncogenesis10 (2), 15. 10.1038/s41389-021-00304-3
95
YiX.TangX. (2021). Exosomes from miR-19b-3p-modified ADSCs inhibit ferroptosis in intracerebral hemorrhage mice. Front. Cell Dev. Biol.9, 661317. 10.3389/fcell.2021.661317
96
ZhangH.DengT.LiuR.NingT.YangH.LiuD.et al (2020a). CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol. Cancer19 (1), 43. 10.1186/s12943-020-01168-8
97
ZhangH.GeZ.WangZ.GaoY.WangY.QuX. (2021a). Circular RNA RHOT1 promotes progression and inhibits ferroptosis via mir-106a-5p/STAT3 axis in breast cancer. Aging (Albany NY)13 (6), 8115–8126. 10.18632/aging.202608
98
ZhangH.HeY.WangJ. X.ChenM. H.XuJ. J.JiangM. H.et al (2020b). miR-30-5p-mediated ferroptosis of trophoblasts is implicated in the pathogenesis of preeclampsia. Redox Biol.29, 101402. 10.1016/j.redox.2019.101402
99
ZhangH. Y.ZhangB. W.ZhangZ. B.DengQ. J. (2020c). Circular RNA TTBK2 regulates cell proliferation, invasion and ferroptosis via miR-761/ITGB8 axis in glioma. Eur. Rev. Med. Pharmacol. Sci.24 (5), 2585–2600. 10.26355/eurrev_202003_20528
100
ZhangK.WuL.ZhangP.LuoM.DuJ.GaoT.et al (2018). miR-9 regulates ferroptosis by targeting glutamic-oxaloacetic transaminase GOT1 in melanoma. Mol. Carcinog.57 (11), 1566–1576. 10.1002/mc.22878
101
ZhangL.YeY.TuH.HildebrandtM. A.ZhaoL.HeymachJ. V.et al (2017). MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk. Ann. Oncol.28 (5), 1124–1129. 10.1093/annonc/mdx046
102
ZhangX.WangL.LiH.ZhangL.ZhengX.ChengW. (2020d). Crosstalk between noncoding RNAs and ferroptosis: New dawn for overcoming cancer progression. Cell death Dis.11 (7), 580. 10.1038/s41419-020-02772-8
103
ZhangX.ZhuJ.XingR.TieY.FuH.ZhengX.et al (2012). miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung cancer77 (3), 488–494. 10.1016/j.lungcan.2012.05.107
104
ZhangY.GuoS.WangS.LiX.HouD.LiH.et al (2021b). LncRNA OIP5-AS1 inhibits ferroptosis in prostate cancer with long-term cadmium exposure through miR-128-3p/SLC7A11 signaling. Ecotoxicol. Environ. Saf.220, 112376. 10.1016/j.ecoenv.2021.112376
105
ZhaoH.LiX.YangL.ZhangL.JiangX.GaoW.et al (2021). Isorhynchophylline relieves ferroptosis-induced nerve damage after intracerebral hemorrhage via miR-122-5p/TP53/slc7a11 pathway. Neurochem. Res.46 (8), 1981–1994. 10.1007/s11064-021-03320-2
106
ZhengH.ShiL.TongC.LiuY.HouM. (2021). circSnx12 is involved in ferroptosis during heart failure by targeting miR-224-5p. Front. Cardiovasc Med.8, 656093. 10.3389/fcvm.2021.656093
107
ZhouX.ZhuoM.ZhangY.ShiE.MaX.LiH. (2021). miR-190a-5p regulates cardiomyocytes response to ferroptosis via directly targeting GLS2. Biochem. Biophys. Res. Commun.566, 9–15. 10.1016/j.bbrc.2021.05.100
108
ZoleaF.BattagliaA. M.ChiarellaE.MalangaD.MarcoC. D.BondH. M.et al (2017). Ferritin heavy subunit silencing blocks the erythroid commitment of K562 cells via miR-150 up-regulation and GATA-1 repression. Int. J. Mol. Sci.18 (10), 2167. 10.3390/ijms18102167
109
ZongC.WangJ.ShiT.-M. (2014). MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumor Biol.35 (12), 12151–12156. 10.1007/s13277-014-2520-x
Summary
Keywords
miRNA, ferroptosis, expression, pathwa, cancer
Citation
Mahmoudi-Lamouki R, Kadkhoda S, Hussen BM and Ghafouri-Fard S (2023) Emerging role of miRNAs in the regulation of ferroptosis. Front. Mol. Biosci. 10:1115996. doi: 10.3389/fmolb.2023.1115996
Received
04 December 2022
Accepted
06 February 2023
Published
15 February 2023
Volume
10 - 2023
Edited by
Wei Ye, Guangdong Academy of Science, China
Reviewed by
Yiqun Jiang, Hunan Normal University, China
Raffaella Faraonio, University of Naples Federico II, Italy
Updates
Copyright
© 2023 Mahmoudi-Lamouki, Kadkhoda, Hussen and Ghafouri-Fard.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Soudeh Ghafouri-Fard, s.ghafourifard@sbmu.ac.ir
This article was submitted to RNA Networks and Biology, a section of the journal Frontiers in Molecular Biosciences
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.